Skip to main content


Latest developments

Leena Hogan in Laboratory thumbnail for video


New radioisotopes:

Various cancers

ANSTO researchers are working with both Australian and international companies to develop the next generation of nuclear medicines to treat cancers and other serious illnesses. These include research into scandium-47 which can be used for both imaging and therapy and terbium-161 which may be able to treat very small cancer metastases. 

Lu-177 Video play button



Prostate cancer and melanoma

ANSTO is the supplier of non-carrier added (n.c.a) Lutetium-177 (Lu-177) used in prostate cancer and melanoma clinical trials being undertaken by ANZUP Cancer Trials Group, Peter MacCallum Cancer Centre and Melanoma & Skin Cancer Trials. 

Radioiummuotherapy video play button



Solid tumours

ANSTO researchers are working with a Sydney-based company GlyTherix on new radioimmunotherapy treatments. Radioimmunotherapy is a combination of immunotherapy, which uses antibodies that specifically target cancer cells, and radioisotopes that can help see and kill cancer cells.

Rhenium video play button Oncobeta


Rhenium SCT (Skin Cancer Therapy):

Non-melanoma skin cancers

ANSTO will be the manufacturing partner in Australia for OncoBeta, a Germany based company. OncoBeta’s medical device uses rhenium-188 (a Beta emitting radioisotope) to treat non-melanoma skin cancers. The OncoBeta product will be the first of its kind to be launched in Australia.

TheraP Infographic

Successful clinical trial for prostate cancer enabled by ANSTO

Read more

Lu-177 hot cell

Applied Molecular Therapies launches its first theranostic product in prostate cancer treatment

Read more

Explore our capabilities

ANSTO manufacture and supply a range of radiopharmaceuticals, radiochemicals, kits and accessories for use in research, industry and the health sector.

Let's connect

view inside hot cell production